{"classes":[{"categories":[{"measurements":[{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline \\>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \\>=50% reduction is presented along with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received GSK525762 80 mg amorphous (amor) free-base tablet along with 6 mg stable isotope (iso) in solution in the fasted state in Period 1 followed by administration of GSK525762 80 mg besylate (bes) tablet along with 6 mg stable iso in solution in the fasted state in Period 2. Participants were then administered GSK525762 30 mg bes tablet along with 6 mg stable iso in solution in the fasted state in Period 3 and GSK525762 80 mg bes tablet was administered with Food and Drug Administration (FDA) recommended high fat breakfast in Period 4.","id":"OG000","title":"80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes"},{"description":"Participants received GSK525762 80 mg bes tablet along with 6 mg stable iso in solution in the fasted state in Period 1 followed by administration GSK525762 80 mg amor free-base tablet along with 6 mg stable iso in solution in the fasted state in Period 2. Participants were then administered GSK525762 30 mg bes tablet along with 6 mg stable iso in solution in the fasted state in Period 3 and GSK525762 80 mg bes tablet was administered with FDA recommended high fat breakfast in Period 4.","id":"OG001","title":"80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.87 months of drug exposure","title":"Number of Participants With PSA50 Response-Besylate Sub-study","type":"PRIMARY","unitOfMeasure":"Participants"}